Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group
- PMID:8596569
- DOI: 10.1056/NEJM199604043341401
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group
Abstract
Background: Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically.
Methods: We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes. Clinical and laboratory evaluations of erection and the feasibility of satisfactoriness of sexual activity as assessed both by the men and by their partners were the primary measures of efficacy.
Results: In a dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose-response relation (P < / = 0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 microg). In a dose-finding study of 201 men, the minimal effective dose was < / = 2 microg in 23, 20, 38 and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psychogenic, or mixed causes, respectively. In a six-month self-injection study in 683 men, the participants reported being able to have sexual activity after 94 percent of the injections. The men and their partners rated the sexual activity as satisfactory after 87 and 86 percent of the injections, respectively. Penile pain, usually mild, occurred in 50 percent of the men at some time but after only 11 percent of the injections. Prolonged erections occurred in 5 percent of the men, priapism in 1 percent, penile fibrotic complications in 2 percent, and hematoma or ecchymosis in 8 percent.
Conclusions: In men with erectile dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side effects.
Comment in
- Injection therapy for erectile dysfunction.Lipshultz LI.Lipshultz LI.N Engl J Med. 1996 Apr 4;334(14):913-4. doi: 10.1056/NEJM199604043341409.N Engl J Med. 1996.PMID:8596577No abstract available.
Similar articles
- The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.[No authors listed][No authors listed]Br J Urol. 1998 Oct;82(4):538-43.Br J Urol. 1998.PMID:9806184
- Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N.Padma-Nathan H, et al.N Engl J Med. 1997 Jan 2;336(1):1-7. doi: 10.1056/NEJM199701023360101.N Engl J Med. 1997.PMID:8970933Clinical Trial.
- Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.Bratus D, Hlebic G, Hajdinjak T.Bratus D, et al.Croat Med J. 2007 Feb;48(1):76-80.Croat Med J. 2007.PMID:17309142Free PMC article.
- [Long-term results of the treatment with intracavernous injection of vasoactive drugs].Rodríguez Vela L, Gonzalvo Ibarra A, Gil Martínez P, Benejan Gual J, Cuesta Presedo JM, Ríoja Sanz LA.Rodríguez Vela L, et al.Arch Esp Urol. 1996 Apr;49(3):257-69.Arch Esp Urol. 1996.PMID:8702347Review.Spanish.
- Intracavernous injection as an option for aging men with erectile dysfunction.Wespes E.Wespes E.Aging Male. 2002 Sep;5(3):177-80.Aging Male. 2002.PMID:12471778Review.
Cited by
- Erectile dysfunction.Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, Maggi M, Nelson CJ, Parish S, Salonia A, Tan R, Mulhall JP, Hellstrom WJ.Yafi FA, et al.Nat Rev Dis Primers. 2016 Feb 4;2:16003. doi: 10.1038/nrdp.2016.3.Nat Rev Dis Primers. 2016.PMID:27188339Free PMC article.Review.
- New treatment for erectile dysfunction.Segraves RT.Segraves RT.Curr Psychiatry Rep. 2000 Jun;2(3):206-10. doi: 10.1007/s11920-996-0009-z.Curr Psychiatry Rep. 2000.PMID:11122957Review.
- A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction.Milligan PA, Marshall SF, Karlsson MO.Milligan PA, et al.Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):45S-52S. doi: 10.1046/j.0306-5251.2001.00032.x.Br J Clin Pharmacol. 2002.PMID:11879259Free PMC article.Clinical Trial.
- Treatment of Priapism Secondary to Drugs for Erectile Dysfunction.Saffon Cuartas JP, Sandoval-Salinas C, Martínez JM, Corredor HA.Saffon Cuartas JP, et al.Adv Urol. 2019 Aug 22;2019:6214921. doi: 10.1155/2019/6214921. eCollection 2019.Adv Urol. 2019.PMID:31534452Free PMC article.
- Erectile Dysfunction: Key Role of Cavernous Smooth Muscle Cells.de Souza ILL, Ferreira EDS, Vasconcelos LHC, Cavalcante FA, da Silva BA.de Souza ILL, et al.Front Pharmacol. 2022 Jul 5;13:895044. doi: 10.3389/fphar.2022.895044. eCollection 2022.Front Pharmacol. 2022.PMID:35865945Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical